Accelerate Antibody Discovery with Label-Free Biolayer Interferometry (BLI)

What if you could measure binding affinity, specificity, and stability—all in real time, without labels or complex workflows?

The discovery and development of therapeutic antibodies demand precision, speed, and scalability across every stage—from transfection and clone selection to stability testing and QC. Biolayer Interferometry (BLI) has become an important technology for researchers striving to generate accurate, high-throughput biomolecular interaction data that support regulatory submissions and biopharmaceutical approvals.

This infographic, developed in partnership with Sartorius, explores how the Octet® R8e system leverages the power of BLI to deliver fast, sensitive, and scalable label-free analysis for each phase of the antibody pipeline. Discover how BLI enables researchers to:

• Rapidly identify and screen productive, stable cell lines
• Characterize binding kinetics, cross-reactivity, and CQAs with minimal sample use
• Monitor cell line conditions and optimize culture performance
• Ensure antibody stability and potency throughout development and scale-up
• Meet stringent regulatory and quality standards through precise, reproducible QC

Download the infographic and see how BLI powers modern antibody development—from discovery to final product release.